The first drug targeting the root cause of Alzheimer’s disease has been approved by the European Medicines Agency. Despite ...

Mere months ago Biogen’s Alzheimer’s drug aducanumab was being written off as the latest amyloid-targeting dud. Now, its back, and with new data that the company says will support an FDA ...

A preprint research letter linking the Alzheimer's drug lecanemab (Leqembi) with excess deaths was withdrawn last week. The ...

The FDA got too close to Biogen during the development of the Alzheimer’s drug aducanumab, according to its own expert advisers who are urging the regulator to reject it in the coming weeks.

"Amyloid-lowering treatments represent an important advance in the treatment of Alzheimer's disease but they are associated ...

appeared to believe would happen when the first beta amyloid-directed monoclonal antibody indicated for Alzheimer’s disease, Aduhelm (aducanumab), was approved in 2021: Namely, rapid adoption ...

A European regulatory committee now recommends approval of the Alzheimer’s treatment lecanemab a few months after rejecting ...

New treatments for Alzheimer disease don’t reverse cognitive symptoms, but they do significantly slow progression. Evidence suggests that earlier treatment is most effective.

5 things to know about Aducanumab, Biogen’s resurrected Alzheimer’s drug The drug had been written off as a failure after a review committee found it to be ineffective. My Mom With Alzheimer ...

driven by monoclonal antibodies like Aducanumab and Leqembi, which offer potential disease-modifying effects for advanced Alzheimer's stages. Alzheimer's Drugs Market Analysis by Distribution ...